Nojan Valadi, MD
Neurology · Opelika, ALNPI 1417171737
Payments from drug & device makers
Across 425 payments — averaging $515.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$131K
- Genentech USA, Inc.$79K
- Portola Pharmaceuticals, LLC$3K
- AstraZeneca$2K
- AbbVie$664
- UCB, Inc.$524
- plus $3K from 29 others
What the payments were for
- Consulting fees$9,2354%
- Speaking & faculty fees$164,50075%
- Travel & lodging$37,07417%
- Food & beverage$8,3924%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 135 | $131,500 |
| Genentech USA, Inc. | 55 | $79,210 |
| Portola Pharmaceuticals, LLC | 11 | $2,516 |
| AstraZeneca(2 entities) | 10 | $2,031 |
| AbbVie(2 entities) | 41 | $664 |
| UCB, Inc. | 30 | $524 |
| Greenwich Biosciences, Inc. | 9 | $344 |
| Pfizer | 27 | $271 |
| Amgen(2 entities) | 11 | $231 |
| Argenx US, Inc. | 10 | $225 |
| Eisai Inc. | 11 | $206 |
| EMD Serono, Inc. | 7 | $175 |
| Acadia Pharmaceuticals Inc | 8 | $168 |
| Biogen | 9 | $151 |
| CSL Behring | 5 | $142 |
| Supernus Pharmaceuticals, Inc. | 6 | $115 |
| Novartis | 6 | $97 |
| Catalyst Pharmaceuticals, Inc. | 4 | $77 |
| Neurocrine Biosciences, Inc. | 4 | $74 |
| Lilly USA, LLC | 3 | $54 |
| Lundbeck LLC | 2 | $53 |
| Teva Pharmaceuticals USA, Inc. | 3 | $48 |
| Sunovion Pharmaceuticals Inc. | 4 | $46 |
| Avanir Pharmaceuticals, Inc. | 2 | $38 |
| MDD US Operations, LLC | 2 | $32 |
| Immedica Pharma US, Inc. | 1 | $29 |
| Tanabe Pharma America, Inc. | 1 | $28 |
| Sanofi | 1 | $24 |
| Cycle Pharmaceuticals Inc | 1 | $22 |
| Jazz Pharmaceuticals Inc. | 1 | $22 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Upsher-smith Laboratories LLC | 1 | $19 |
| Axsome Therapeutics, Inc. | 1 | $17 |
| Abbott | 1 | $16 |
| Neurelis, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$219,201 in reported general payments places this provider in the 85th percentile of 255 neurology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VimpatLacosamide | 21 | $46,495 |
| BriviactBrivaracetam | 13 | $21,406 |
| SilenorDoxepin Hcl | 12 | $7,146 |
| Rivastigmine | 15 | $4,914 |
| Donepezil Hcl | 177 | $3,451 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 91 | $3,137 |
| Pyridostigmine Bromide | 14 | $2,652 |
| Memantine Hcl | 82 | $1,621 |
| Levetiracetam | 43 | $1,613 |
| Entacapone | 15 | $1,371 |
| Gabapentin | 85 | $1,340 |
| RivastigmineRivastigmine Tartrate | 20 | $1,021 |
| Carbamazepine | 12 | $966 |
| Primidone | 30 | $919 |
| Rasagiline Mesylate | 13 | $815 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| UCB, Inc.Vimpat, Briviact | $524 | $67,90034 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 255 neurology providers in Alabama.
Other neurology in Opelika
- Emily RiserBirmingham$7.1M
- Christopher LagankeCullman$5.9M
- Louis NaborsBirmingham$3.2M
- Belinda Savage-EdwardsHuntsville$2.8M
- Khurram BashirBirmingham$2.8M
- David GeldmacherBirmingham$2.6M
- Victor SungBirmingham$2M
- Mina LobbousBirmingham$1.8M
- Diane CounceBirmingham$1.4M
- Judy WhiteFlorala$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.